Fukumoto Manabu, Nakayama Kentaro
Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Pathol Int. 2006 May;56(5):233-9. doi: 10.1111/j.1440-1827.2006.01960.x.
Ovarian tumors of low malignant potential (LMP) are intermediate between benign adenoma and frank ovarian carcinoma, and are characterized by the absence of destructive stromal invasion, or microinvasion. If LMP did not develop into invasive carcinoma, then a minimally invasive simple treatment could be chosen. However, histological diagnosis cannot completely predict the prognosis of patients with ovarian tumors. It was found that mucinous LMP is most frequent in Japan, whereas serous LMP is the most common in Western countries. Mucinous LMP with loss of heterozygosity (LOH) at chromosomes 5q14-21 and 17q11.2, and serous LMP were suggested to be precursor lesions of ovarian carcinomas. Follow-up study revealed that patients with mucinous LMP who had LOH at 19q12 and/or Xq11-12 were at the greatest risk of progression. It is concluded that molecular genetic analysis such as LOH study could predict prognosis and aid in treatment decision-making. The present review describes molecular genetic changes of LMP and presents problems on LMP that remain to be elucidated.
卵巢低恶性潜能肿瘤（LMP）介于良性腺瘤和典型卵巢癌之间，其特征是不存在破坏性间质浸润或微浸润。如果LMP未发展为浸润性癌，那么可以选择微创的简单治疗方法。然而，组织学诊断并不能完全预测卵巢肿瘤患者的预后。据发现，黏液性LMP在日本最为常见，而浆液性LMP在西方国家最为常见。5号染色体q14 - 21区域和17号染色体q11.2区域杂合性缺失（LOH）的黏液性LMP以及浆液性LMP被认为是卵巢癌的前驱病变。随访研究显示，19号染色体q12区域和/或X染色体q11 - 12区域存在LOH的黏液性LMP患者进展风险最大。结论是，诸如LOH研究等分子遗传学分析可以预测预后并有助于治疗决策。本综述描述了LMP的分子遗传学变化，并提出了LMP仍有待阐明的问题。
